Pyrotinib Clinical Trials
15 recruitingDrug
Phase 211Phase 41Phase 31Not Applicable1Phase 11
Showing 1–15 of 15 trials
Recruiting
Phase 2
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
MutationLung Cancer Stage III
Sun Yat-sen University120 enrolled1 locationNCT06563999
Recruiting
Phase 2
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Metastatic Breast Cancer
Henan Cancer Hospital150 enrolled1 locationNCT05769010
Recruiting
Phase 2
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University200 enrolled1 locationNCT07340398
Recruiting
Phase 2
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Peking Union Medical College Hospital18 enrolled1 locationNCT05751018
Recruiting
Phase 2
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin186 enrolled1 locationNCT07180082
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmBreast Tumors
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
HER2 + Breast Cancer
The First Affiliated Hospital with Nanjing Medical University74 enrolled1 locationNCT07065435
Recruiting
Phase 1Phase 2
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Breast Cancer MetastaticBreast Cancer Brain Metastases
Fudan University74 enrolled1 locationNCT06718933
Recruiting
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
HER2-positive Breast Cancer
zhangjie60 enrolled1 locationNCT06754059
Recruiting
Phase 2
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
HER2-positive Breast Cancer
Shengjing Hospital65 enrolled1 locationNCT05635487
Recruiting
Phase 4
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Advanced Breast CancerHER2-positive Breast Cancer
Hebei Medical University Fourth Hospital100 enrolled1 locationNCT06217185
Recruiting
Phase 3
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
HER2-positive Metastatic Breast CancerFirst-line Treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University312 enrolled1 locationNCT06278870
Recruiting
Not Applicable
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
Breast Neoplasm Female
Wang Ouchen154 enrolled1 locationNCT06234137
Recruiting
Phase 2
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University188 enrolled1 locationNCT05834764
Recruiting
Phase 2
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Breast Cancer
Shengjing Hospital236 enrolled1 locationNCT05638594